Oral Antibiotics Comprehensive Study by Type (Branded, Generic), Application (Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)), Urinary Acquired Tract Infections (UTIS), Dental (Combination, and Monotherapies), Others), Spectrum of Activity (Broad-Spectrum Antibiotic, Narrow-Spectrum Antibiotic), Drug Origin (Natural, Semisynthetic, Synthetic), Class (Beta-Lactam and Beta-Lactamase Inhibitors, Quinolone, Macrolide, Others) Players and Region - Global Market Outlook to 2026

Report Objectives / Segmentation Covered

• Branded
• Generic

• Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
• Urinary Acquired Tract Infections (UTIS)
• Dental (Combination, and Monotherapies)
• Others

• Broad-Spectrum Antibiotic
• Narrow-Spectrum Antibiotic

• Natural
• Semisynthetic
• Synthetic

• Beta-Lactam and Beta-Lactamase Inhibitors
• Quinolone
• Macrolide
• Others

• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • Italy
  • United Kingdom
  • Netherlands
  • Rest of Europe
• MEA
  • Middle East
  • Africa
• North America
  • United States
  • Canada
  • Mexico

• 1. Market Overview
  • 1.1. Introduction
  • 1.2. Scope/Objective of the Study
    • 1.2.1. Research Objective
• 2. Executive Summary
  • 2.1. Introduction
• 3. Market Dynamics
  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Rising in Prevalence of Infectious Diseases across the Globe
    • 3.2.2. Increase in Demand for Antibiotics, owing to Increased Consumption in Low- and Middle-Income Countries
  • 3.3. Market Challenges
    • 3.3.1. Presence of Several Antibiotics
  • 3.4. Market Trends
    • 3.4.1. Development of Novel Approaches for new Antibiotics to Treat Bacterial Infections
• 4. Market Factor Analysis
  • 4.1. Porters Five Forces
  • 4.2. Supply/Value Chain
  • 4.3. PESTEL analysis
  • 4.4. Market Entropy
  • 4.5. Patent/Trademark Analysis
• 5. Global Oral Antibiotics, by Type, Application, Spectrum of Activity, Drug Origin, Class and Region (value, volume and price ) (2015-2020)
  • 5.1. Introduction
  • 5.2. Global Oral Antibiotics (Value)
    • 5.2.1. Global Oral Antibiotics by: Type (Value)
      • 5.2.1.1. Branded
      • 5.2.1.2. Generic
    • 5.2.2. Global Oral Antibiotics by: Application (Value)
      • 5.2.2.1. Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
      • 5.2.2.2. Urinary Acquired Tract Infections (UTIS)
      • 5.2.2.3. Dental (Combination, and Monotherapies)
      • 5.2.2.4. Others
    • 5.2.3. Global Oral Antibiotics by: Spectrum of Activity (Value)
      • 5.2.3.1. Broad-Spectrum Antibiotic
      • 5.2.3.2. Narrow-Spectrum Antibiotic
    • 5.2.4. Global Oral Antibiotics by: Drug Origin (Value)
      • 5.2.4.1. Natural
      • 5.2.4.2. Semisynthetic
      • 5.2.4.3. Synthetic
    • 5.2.5. Global Oral Antibiotics by: Class (Value)
      • 5.2.5.1. Beta-Lactam and Beta-Lactamase Inhibitors
      • 5.2.5.2. Quinolone
      • 5.2.5.3. Macrolide
      • 5.2.5.4. Others
    • 5.2.6. Global Oral Antibiotics Region
      • 5.2.6.1. South America
        • 5.2.6.1.1. Brazil
        • 5.2.6.1.2. Argentina
        • 5.2.6.1.3. Rest of South America
      • 5.2.6.2. Asia Pacific
        • 5.2.6.2.1. China
        • 5.2.6.2.2. Japan
        • 5.2.6.2.3. India
        • 5.2.6.2.4. South Korea
        • 5.2.6.2.5. Taiwan
        • 5.2.6.2.6. Australia
        • 5.2.6.2.7. Rest of Asia-Pacific
      • 5.2.6.3. Europe
        • 5.2.6.3.1. Germany
        • 5.2.6.3.2. France
        • 5.2.6.3.3. Italy
        • 5.2.6.3.4. United Kingdom
        • 5.2.6.3.5. Netherlands
        • 5.2.6.3.6. Rest of Europe
      • 5.2.6.4. MEA
        • 5.2.6.4.1. Middle East
        • 5.2.6.4.2. Africa
      • 5.2.6.5. North America
        • 5.2.6.5.1. United States
        • 5.2.6.5.2. Canada
        • 5.2.6.5.3. Mexico
  • 5.3. Global Oral Antibiotics (Volume)
    • 5.3.1. Global Oral Antibiotics by: Type (Volume)
      • 5.3.1.1. Branded
      • 5.3.1.2. Generic
    • 5.3.2. Global Oral Antibiotics by: Application (Volume)
      • 5.3.2.1. Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
      • 5.3.2.2. Urinary Acquired Tract Infections (UTIS)
      • 5.3.2.3. Dental (Combination, and Monotherapies)
      • 5.3.2.4. Others
    • 5.3.3. Global Oral Antibiotics by: Spectrum of Activity (Volume)
      • 5.3.3.1. Broad-Spectrum Antibiotic
      • 5.3.3.2. Narrow-Spectrum Antibiotic
    • 5.3.4. Global Oral Antibiotics by: Drug Origin (Volume)
      • 5.3.4.1. Natural
      • 5.3.4.2. Semisynthetic
      • 5.3.4.3. Synthetic
    • 5.3.5. Global Oral Antibiotics by: Class (Volume)
      • 5.3.5.1. Beta-Lactam and Beta-Lactamase Inhibitors
      • 5.3.5.2. Quinolone
      • 5.3.5.3. Macrolide
      • 5.3.5.4. Others
    • 5.3.6. Global Oral Antibiotics Region
      • 5.3.6.1. South America
        • 5.3.6.1.1. Brazil
        • 5.3.6.1.2. Argentina
        • 5.3.6.1.3. Rest of South America
      • 5.3.6.2. Asia Pacific
        • 5.3.6.2.1. China
        • 5.3.6.2.2. Japan
        • 5.3.6.2.3. India
        • 5.3.6.2.4. South Korea
        • 5.3.6.2.5. Taiwan
        • 5.3.6.2.6. Australia
        • 5.3.6.2.7. Rest of Asia-Pacific
      • 5.3.6.3. Europe
        • 5.3.6.3.1. Germany
        • 5.3.6.3.2. France
        • 5.3.6.3.3. Italy
        • 5.3.6.3.4. United Kingdom
        • 5.3.6.3.5. Netherlands
        • 5.3.6.3.6. Rest of Europe
      • 5.3.6.4. MEA
        • 5.3.6.4.1. Middle East
        • 5.3.6.4.2. Africa
      • 5.3.6.5. North America
        • 5.3.6.5.1. United States
        • 5.3.6.5.2. Canada
        • 5.3.6.5.3. Mexico
  • 5.4. Global Oral Antibiotics (Price)
    • 5.4.1. Global Oral Antibiotics by: Type (Price)
• 6. Oral Antibiotics: Manufacturers/Players Analysis
  • 6.1. Competitive Landscape
    • 6.1.1. Market Share Analysis
      • 6.1.1.1. Top 3
      • 6.1.1.2. Top 5
  • 6.2. Peer Group Analysis (2020)
  • 6.3. BCG Matrix
  • 6.4. Company Profile
    • 6.4.1. Abbott Laboratories (United States)
      • 6.4.1.1. Business Overview
      • 6.4.1.2. Products/Services Offerings
      • 6.4.1.3. Financial Analysis
      • 6.4.1.4. SWOT Analysis
    • 6.4.2. Allergan Plc. (Ireland)
      • 6.4.2.1. Business Overview
      • 6.4.2.2. Products/Services Offerings
      • 6.4.2.3. Financial Analysis
      • 6.4.2.4. SWOT Analysis
    • 6.4.3. F. Hoffmann-La Roche Ltd. (Switzerland)
      • 6.4.3.1. Business Overview
      • 6.4.3.2. Products/Services Offerings
      • 6.4.3.3. Financial Analysis
      • 6.4.3.4. SWOT Analysis
    • 6.4.4. GlaxoSmithKline plc (United Kingdom)
      • 6.4.4.1. Business Overview
      • 6.4.4.2. Products/Services Offerings
      • 6.4.4.3. Financial Analysis
      • 6.4.4.4. SWOT Analysis
    • 6.4.5. Merck & Co. Inc. (United States)
      • 6.4.5.1. Business Overview
      • 6.4.5.2. Products/Services Offerings
      • 6.4.5.3. Financial Analysis
      • 6.4.5.4. SWOT Analysis
    • 6.4.6. Mylan N.V. (United States)
      • 6.4.6.1. Business Overview
      • 6.4.6.2. Products/Services Offerings
      • 6.4.6.3. Financial Analysis
      • 6.4.6.4. SWOT Analysis
    • 6.4.7. Novartis International AG (Sandoz)
      • 6.4.7.1. Business Overview
      • 6.4.7.2. Products/Services Offerings
      • 6.4.7.3. Financial Analysis
      • 6.4.7.4. SWOT Analysis
    • 6.4.8. Pfizer Inc. (United States)
      • 6.4.8.1. Business Overview
      • 6.4.8.2. Products/Services Offerings
      • 6.4.8.3. Financial Analysis
      • 6.4.8.4. SWOT Analysis
    • 6.4.9. Sanofi (France)
      • 6.4.9.1. Business Overview
      • 6.4.9.2. Products/Services Offerings
      • 6.4.9.3. Financial Analysis
      • 6.4.9.4. SWOT Analysis
    • 6.4.10. Teva Pharmaceutical Industries Ltd. (Israel)
      • 6.4.10.1. Business Overview
      • 6.4.10.2. Products/Services Offerings
      • 6.4.10.3. Financial Analysis
      • 6.4.10.4. SWOT Analysis
• 7. Global Oral Antibiotics Sale, by Type, Application, Spectrum of Activity, Drug Origin, Class and Region (value, volume and price ) (2021-2026)
  • 7.1. Introduction
  • 7.2. Global Oral Antibiotics (Value)
    • 7.2.1. Global Oral Antibiotics by: Type (Value)
      • 7.2.1.1. Branded
      • 7.2.1.2. Generic
    • 7.2.2. Global Oral Antibiotics by: Application (Value)
      • 7.2.2.1. Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
      • 7.2.2.2. Urinary Acquired Tract Infections (UTIS)
      • 7.2.2.3. Dental (Combination, and Monotherapies)
      • 7.2.2.4. Others
    • 7.2.3. Global Oral Antibiotics by: Spectrum of Activity (Value)
      • 7.2.3.1. Broad-Spectrum Antibiotic
      • 7.2.3.2. Narrow-Spectrum Antibiotic
    • 7.2.4. Global Oral Antibiotics by: Drug Origin (Value)
      • 7.2.4.1. Natural
      • 7.2.4.2. Semisynthetic
      • 7.2.4.3. Synthetic
    • 7.2.5. Global Oral Antibiotics by: Class (Value)
      • 7.2.5.1. Beta-Lactam and Beta-Lactamase Inhibitors
      • 7.2.5.2. Quinolone
      • 7.2.5.3. Macrolide
      • 7.2.5.4. Others
    • 7.2.6. Global Oral Antibiotics Region
      • 7.2.6.1. South America
        • 7.2.6.1.1. Brazil
        • 7.2.6.1.2. Argentina
        • 7.2.6.1.3. Rest of South America
      • 7.2.6.2. Asia Pacific
        • 7.2.6.2.1. China
        • 7.2.6.2.2. Japan
        • 7.2.6.2.3. India
        • 7.2.6.2.4. South Korea
        • 7.2.6.2.5. Taiwan
        • 7.2.6.2.6. Australia
        • 7.2.6.2.7. Rest of Asia-Pacific
      • 7.2.6.3. Europe
        • 7.2.6.3.1. Germany
        • 7.2.6.3.2. France
        • 7.2.6.3.3. Italy
        • 7.2.6.3.4. United Kingdom
        • 7.2.6.3.5. Netherlands
        • 7.2.6.3.6. Rest of Europe
      • 7.2.6.4. MEA
        • 7.2.6.4.1. Middle East
        • 7.2.6.4.2. Africa
      • 7.2.6.5. North America
        • 7.2.6.5.1. United States
        • 7.2.6.5.2. Canada
        • 7.2.6.5.3. Mexico
  • 7.3. Global Oral Antibiotics (Volume)
    • 7.3.1. Global Oral Antibiotics by: Type (Volume)
      • 7.3.1.1. Branded
      • 7.3.1.2. Generic
    • 7.3.2. Global Oral Antibiotics by: Application (Volume)
      • 7.3.2.1. Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
      • 7.3.2.2. Urinary Acquired Tract Infections (UTIS)
      • 7.3.2.3. Dental (Combination, and Monotherapies)
      • 7.3.2.4. Others
    • 7.3.3. Global Oral Antibiotics by: Spectrum of Activity (Volume)
      • 7.3.3.1. Broad-Spectrum Antibiotic
      • 7.3.3.2. Narrow-Spectrum Antibiotic
    • 7.3.4. Global Oral Antibiotics by: Drug Origin (Volume)
      • 7.3.4.1. Natural
      • 7.3.4.2. Semisynthetic
      • 7.3.4.3. Synthetic
    • 7.3.5. Global Oral Antibiotics by: Class (Volume)
      • 7.3.5.1. Beta-Lactam and Beta-Lactamase Inhibitors
      • 7.3.5.2. Quinolone
      • 7.3.5.3. Macrolide
      • 7.3.5.4. Others
    • 7.3.6. Global Oral Antibiotics Region
      • 7.3.6.1. South America
        • 7.3.6.1.1. Brazil
        • 7.3.6.1.2. Argentina
        • 7.3.6.1.3. Rest of South America
      • 7.3.6.2. Asia Pacific
        • 7.3.6.2.1. China
        • 7.3.6.2.2. Japan
        • 7.3.6.2.3. India
        • 7.3.6.2.4. South Korea
        • 7.3.6.2.5. Taiwan
        • 7.3.6.2.6. Australia
        • 7.3.6.2.7. Rest of Asia-Pacific
      • 7.3.6.3. Europe
        • 7.3.6.3.1. Germany
        • 7.3.6.3.2. France
        • 7.3.6.3.3. Italy
        • 7.3.6.3.4. United Kingdom
        • 7.3.6.3.5. Netherlands
        • 7.3.6.3.6. Rest of Europe
      • 7.3.6.4. MEA
        • 7.3.6.4.1. Middle East
        • 7.3.6.4.2. Africa
      • 7.3.6.5. North America
        • 7.3.6.5.1. United States
        • 7.3.6.5.2. Canada
        • 7.3.6.5.3. Mexico
  • 7.4. Global Oral Antibiotics (Price)
    • 7.4.1. Global Oral Antibiotics by: Type (Price)
• 8. Appendix
  • 8.1. Acronyms
• 9. Methodology and Data Source
  • 9.1. Methodology/Research Approach
    • 9.1.1. Research Programs/Design
    • 9.1.2. Market Size Estimation
    • 9.1.3. Market Breakdown and Data Triangulation
  • 9.2. Data Source
    • 9.2.1. Secondary Sources
    • 9.2.2. Primary Sources
  • 9.3. Disclaimer

• Table 1. Oral Antibiotics: by Type(USD Million)
• Table 2. Oral Antibiotics Branded , by Region USD Million (2015-2020)
• Table 3. Oral Antibiotics Generic , by Region USD Million (2015-2020)
• Table 4. Oral Antibiotics: by Application(USD Million)
• Table 5. Oral Antibiotics Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)) , by Region USD Million (2015-2020)
• Table 6. Oral Antibiotics Urinary Acquired Tract Infections (UTIS) , by Region USD Million (2015-2020)
• Table 7. Oral Antibiotics Dental (Combination, and Monotherapies) , by Region USD Million (2015-2020)
• Table 8. Oral Antibiotics Others , by Region USD Million (2015-2020)
• Table 9. Oral Antibiotics: by Spectrum of Activity(USD Million)
• Table 10. Oral Antibiotics Broad-Spectrum Antibiotic , by Region USD Million (2015-2020)
• Table 11. Oral Antibiotics Narrow-Spectrum Antibiotic , by Region USD Million (2015-2020)
• Table 12. Oral Antibiotics: by Drug Origin(USD Million)
• Table 13. Oral Antibiotics Natural , by Region USD Million (2015-2020)
• Table 14. Oral Antibiotics Semisynthetic , by Region USD Million (2015-2020)
• Table 15. Oral Antibiotics Synthetic , by Region USD Million (2015-2020)
• Table 16. Oral Antibiotics: by Class(USD Million)
• Table 17. Oral Antibiotics Beta-Lactam and Beta-Lactamase Inhibitors , by Region USD Million (2015-2020)
• Table 18. Oral Antibiotics Quinolone , by Region USD Million (2015-2020)
• Table 19. Oral Antibiotics Macrolide , by Region USD Million (2015-2020)
• Table 20. Oral Antibiotics Others , by Region USD Million (2015-2020)
• Table 21. South America Oral Antibiotics, by Country USD Million (2015-2020)
• Table 22. South America Oral Antibiotics, by Type USD Million (2015-2020)
• Table 23. South America Oral Antibiotics, by Application USD Million (2015-2020)
• Table 24. South America Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 25. South America Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 26. South America Oral Antibiotics, by Class USD Million (2015-2020)
• Table 27. Brazil Oral Antibiotics, by Type USD Million (2015-2020)
• Table 28. Brazil Oral Antibiotics, by Application USD Million (2015-2020)
• Table 29. Brazil Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 30. Brazil Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 31. Brazil Oral Antibiotics, by Class USD Million (2015-2020)
• Table 32. Argentina Oral Antibiotics, by Type USD Million (2015-2020)
• Table 33. Argentina Oral Antibiotics, by Application USD Million (2015-2020)
• Table 34. Argentina Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 35. Argentina Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 36. Argentina Oral Antibiotics, by Class USD Million (2015-2020)
• Table 37. Rest of South America Oral Antibiotics, by Type USD Million (2015-2020)
• Table 38. Rest of South America Oral Antibiotics, by Application USD Million (2015-2020)
• Table 39. Rest of South America Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 40. Rest of South America Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 41. Rest of South America Oral Antibiotics, by Class USD Million (2015-2020)
• Table 42. Asia Pacific Oral Antibiotics, by Country USD Million (2015-2020)
• Table 43. Asia Pacific Oral Antibiotics, by Type USD Million (2015-2020)
• Table 44. Asia Pacific Oral Antibiotics, by Application USD Million (2015-2020)
• Table 45. Asia Pacific Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 46. Asia Pacific Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 47. Asia Pacific Oral Antibiotics, by Class USD Million (2015-2020)
• Table 48. China Oral Antibiotics, by Type USD Million (2015-2020)
• Table 49. China Oral Antibiotics, by Application USD Million (2015-2020)
• Table 50. China Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 51. China Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 52. China Oral Antibiotics, by Class USD Million (2015-2020)
• Table 53. Japan Oral Antibiotics, by Type USD Million (2015-2020)
• Table 54. Japan Oral Antibiotics, by Application USD Million (2015-2020)
• Table 55. Japan Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 56. Japan Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 57. Japan Oral Antibiotics, by Class USD Million (2015-2020)
• Table 58. India Oral Antibiotics, by Type USD Million (2015-2020)
• Table 59. India Oral Antibiotics, by Application USD Million (2015-2020)
• Table 60. India Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 61. India Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 62. India Oral Antibiotics, by Class USD Million (2015-2020)
• Table 63. South Korea Oral Antibiotics, by Type USD Million (2015-2020)
• Table 64. South Korea Oral Antibiotics, by Application USD Million (2015-2020)
• Table 65. South Korea Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 66. South Korea Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 67. South Korea Oral Antibiotics, by Class USD Million (2015-2020)
• Table 68. Taiwan Oral Antibiotics, by Type USD Million (2015-2020)
• Table 69. Taiwan Oral Antibiotics, by Application USD Million (2015-2020)
• Table 70. Taiwan Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 71. Taiwan Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 72. Taiwan Oral Antibiotics, by Class USD Million (2015-2020)
• Table 73. Australia Oral Antibiotics, by Type USD Million (2015-2020)
• Table 74. Australia Oral Antibiotics, by Application USD Million (2015-2020)
• Table 75. Australia Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 76. Australia Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 77. Australia Oral Antibiotics, by Class USD Million (2015-2020)
• Table 78. Rest of Asia-Pacific Oral Antibiotics, by Type USD Million (2015-2020)
• Table 79. Rest of Asia-Pacific Oral Antibiotics, by Application USD Million (2015-2020)
• Table 80. Rest of Asia-Pacific Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 81. Rest of Asia-Pacific Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 82. Rest of Asia-Pacific Oral Antibiotics, by Class USD Million (2015-2020)
• Table 83. Europe Oral Antibiotics, by Country USD Million (2015-2020)
• Table 84. Europe Oral Antibiotics, by Type USD Million (2015-2020)
• Table 85. Europe Oral Antibiotics, by Application USD Million (2015-2020)
• Table 86. Europe Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 87. Europe Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 88. Europe Oral Antibiotics, by Class USD Million (2015-2020)
• Table 89. Germany Oral Antibiotics, by Type USD Million (2015-2020)
• Table 90. Germany Oral Antibiotics, by Application USD Million (2015-2020)
• Table 91. Germany Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 92. Germany Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 93. Germany Oral Antibiotics, by Class USD Million (2015-2020)
• Table 94. France Oral Antibiotics, by Type USD Million (2015-2020)
• Table 95. France Oral Antibiotics, by Application USD Million (2015-2020)
• Table 96. France Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 97. France Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 98. France Oral Antibiotics, by Class USD Million (2015-2020)
• Table 99. Italy Oral Antibiotics, by Type USD Million (2015-2020)
• Table 100. Italy Oral Antibiotics, by Application USD Million (2015-2020)
• Table 101. Italy Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 102. Italy Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 103. Italy Oral Antibiotics, by Class USD Million (2015-2020)
• Table 104. United Kingdom Oral Antibiotics, by Type USD Million (2015-2020)
• Table 105. United Kingdom Oral Antibiotics, by Application USD Million (2015-2020)
• Table 106. United Kingdom Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 107. United Kingdom Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 108. United Kingdom Oral Antibiotics, by Class USD Million (2015-2020)
• Table 109. Netherlands Oral Antibiotics, by Type USD Million (2015-2020)
• Table 110. Netherlands Oral Antibiotics, by Application USD Million (2015-2020)
• Table 111. Netherlands Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 112. Netherlands Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 113. Netherlands Oral Antibiotics, by Class USD Million (2015-2020)
• Table 114. Rest of Europe Oral Antibiotics, by Type USD Million (2015-2020)
• Table 115. Rest of Europe Oral Antibiotics, by Application USD Million (2015-2020)
• Table 116. Rest of Europe Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 117. Rest of Europe Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 118. Rest of Europe Oral Antibiotics, by Class USD Million (2015-2020)
• Table 119. MEA Oral Antibiotics, by Country USD Million (2015-2020)
• Table 120. MEA Oral Antibiotics, by Type USD Million (2015-2020)
• Table 121. MEA Oral Antibiotics, by Application USD Million (2015-2020)
• Table 122. MEA Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 123. MEA Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 124. MEA Oral Antibiotics, by Class USD Million (2015-2020)
• Table 125. Middle East Oral Antibiotics, by Type USD Million (2015-2020)
• Table 126. Middle East Oral Antibiotics, by Application USD Million (2015-2020)
• Table 127. Middle East Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 128. Middle East Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 129. Middle East Oral Antibiotics, by Class USD Million (2015-2020)
• Table 130. Africa Oral Antibiotics, by Type USD Million (2015-2020)
• Table 131. Africa Oral Antibiotics, by Application USD Million (2015-2020)
• Table 132. Africa Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 133. Africa Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 134. Africa Oral Antibiotics, by Class USD Million (2015-2020)
• Table 135. North America Oral Antibiotics, by Country USD Million (2015-2020)
• Table 136. North America Oral Antibiotics, by Type USD Million (2015-2020)
• Table 137. North America Oral Antibiotics, by Application USD Million (2015-2020)
• Table 138. North America Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 139. North America Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 140. North America Oral Antibiotics, by Class USD Million (2015-2020)
• Table 141. United States Oral Antibiotics, by Type USD Million (2015-2020)
• Table 142. United States Oral Antibiotics, by Application USD Million (2015-2020)
• Table 143. United States Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 144. United States Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 145. United States Oral Antibiotics, by Class USD Million (2015-2020)
• Table 146. Canada Oral Antibiotics, by Type USD Million (2015-2020)
• Table 147. Canada Oral Antibiotics, by Application USD Million (2015-2020)
• Table 148. Canada Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 149. Canada Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 150. Canada Oral Antibiotics, by Class USD Million (2015-2020)
• Table 151. Mexico Oral Antibiotics, by Type USD Million (2015-2020)
• Table 152. Mexico Oral Antibiotics, by Application USD Million (2015-2020)
• Table 153. Mexico Oral Antibiotics, by Spectrum of Activity USD Million (2015-2020)
• Table 154. Mexico Oral Antibiotics, by Drug Origin USD Million (2015-2020)
• Table 155. Mexico Oral Antibiotics, by Class USD Million (2015-2020)
• Table 156. Oral Antibiotics Sales: by Type(KG)
• Table 157. Oral Antibiotics Sales Branded , by Region KG (2015-2020)
• Table 158. Oral Antibiotics Sales Generic , by Region KG (2015-2020)
• Table 159. Oral Antibiotics Sales: by Application(KG)
• Table 160. Oral Antibiotics Sales Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)) , by Region KG (2015-2020)
• Table 161. Oral Antibiotics Sales Urinary Acquired Tract Infections (UTIS) , by Region KG (2015-2020)
• Table 162. Oral Antibiotics Sales Dental (Combination, and Monotherapies) , by Region KG (2015-2020)
• Table 163. Oral Antibiotics Sales Others , by Region KG (2015-2020)
• Table 164. Oral Antibiotics Sales: by Spectrum of Activity(KG)
• Table 165. Oral Antibiotics Sales Broad-Spectrum Antibiotic , by Region KG (2015-2020)
• Table 166. Oral Antibiotics Sales Narrow-Spectrum Antibiotic , by Region KG (2015-2020)
• Table 167. Oral Antibiotics Sales: by Drug Origin(KG)
• Table 168. Oral Antibiotics Sales Natural , by Region KG (2015-2020)
• Table 169. Oral Antibiotics Sales Semisynthetic , by Region KG (2015-2020)
• Table 170. Oral Antibiotics Sales Synthetic , by Region KG (2015-2020)
• Table 171. Oral Antibiotics Sales: by Class(KG)
• Table 172. Oral Antibiotics Sales Beta-Lactam and Beta-Lactamase Inhibitors , by Region KG (2015-2020)
• Table 173. Oral Antibiotics Sales Quinolone , by Region KG (2015-2020)
• Table 174. Oral Antibiotics Sales Macrolide , by Region KG (2015-2020)
• Table 175. Oral Antibiotics Sales Others , by Region KG (2015-2020)
• Table 176. South America Oral Antibiotics Sales, by Country KG (2015-2020)
• Table 177. South America Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 178. South America Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 179. South America Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 180. South America Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 181. South America Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 182. Brazil Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 183. Brazil Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 184. Brazil Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 185. Brazil Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 186. Brazil Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 187. Argentina Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 188. Argentina Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 189. Argentina Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 190. Argentina Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 191. Argentina Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 192. Rest of South America Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 193. Rest of South America Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 194. Rest of South America Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 195. Rest of South America Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 196. Rest of South America Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 197. Asia Pacific Oral Antibiotics Sales, by Country KG (2015-2020)
• Table 198. Asia Pacific Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 199. Asia Pacific Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 200. Asia Pacific Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 201. Asia Pacific Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 202. Asia Pacific Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 203. China Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 204. China Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 205. China Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 206. China Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 207. China Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 208. Japan Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 209. Japan Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 210. Japan Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 211. Japan Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 212. Japan Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 213. India Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 214. India Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 215. India Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 216. India Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 217. India Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 218. South Korea Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 219. South Korea Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 220. South Korea Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 221. South Korea Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 222. South Korea Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 223. Taiwan Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 224. Taiwan Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 225. Taiwan Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 226. Taiwan Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 227. Taiwan Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 228. Australia Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 229. Australia Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 230. Australia Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 231. Australia Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 232. Australia Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 233. Rest of Asia-Pacific Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 234. Rest of Asia-Pacific Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 235. Rest of Asia-Pacific Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 236. Rest of Asia-Pacific Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 237. Rest of Asia-Pacific Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 238. Europe Oral Antibiotics Sales, by Country KG (2015-2020)
• Table 239. Europe Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 240. Europe Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 241. Europe Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 242. Europe Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 243. Europe Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 244. Germany Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 245. Germany Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 246. Germany Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 247. Germany Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 248. Germany Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 249. France Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 250. France Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 251. France Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 252. France Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 253. France Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 254. Italy Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 255. Italy Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 256. Italy Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 257. Italy Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 258. Italy Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 259. United Kingdom Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 260. United Kingdom Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 261. United Kingdom Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 262. United Kingdom Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 263. United Kingdom Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 264. Netherlands Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 265. Netherlands Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 266. Netherlands Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 267. Netherlands Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 268. Netherlands Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 269. Rest of Europe Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 270. Rest of Europe Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 271. Rest of Europe Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 272. Rest of Europe Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 273. Rest of Europe Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 274. MEA Oral Antibiotics Sales, by Country KG (2015-2020)
• Table 275. MEA Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 276. MEA Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 277. MEA Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 278. MEA Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 279. MEA Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 280. Middle East Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 281. Middle East Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 282. Middle East Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 283. Middle East Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 284. Middle East Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 285. Africa Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 286. Africa Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 287. Africa Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 288. Africa Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 289. Africa Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 290. North America Oral Antibiotics Sales, by Country KG (2015-2020)
• Table 291. North America Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 292. North America Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 293. North America Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 294. North America Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 295. North America Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 296. United States Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 297. United States Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 298. United States Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 299. United States Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 300. United States Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 301. Canada Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 302. Canada Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 303. Canada Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 304. Canada Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 305. Canada Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 306. Mexico Oral Antibiotics Sales, by Type KG (2015-2020)
• Table 307. Mexico Oral Antibiotics Sales, by Application KG (2015-2020)
• Table 308. Mexico Oral Antibiotics Sales, by Spectrum of Activity KG (2015-2020)
• Table 309. Mexico Oral Antibiotics Sales, by Drug Origin KG (2015-2020)
• Table 310. Mexico Oral Antibiotics Sales, by Class KG (2015-2020)
• Table 311. Oral Antibiotics: by Type(USD/Units)
• Table 312. Company Basic Information, Sales Area and Its Competitors
• Table 313. Company Basic Information, Sales Area and Its Competitors
• Table 314. Company Basic Information, Sales Area and Its Competitors
• Table 315. Company Basic Information, Sales Area and Its Competitors
• Table 316. Company Basic Information, Sales Area and Its Competitors
• Table 317. Company Basic Information, Sales Area and Its Competitors
• Table 318. Company Basic Information, Sales Area and Its Competitors
• Table 319. Company Basic Information, Sales Area and Its Competitors
• Table 320. Company Basic Information, Sales Area and Its Competitors
• Table 321. Company Basic Information, Sales Area and Its Competitors
• Table 322. Oral Antibiotics: by Type(USD Million)
• Table 323. Oral Antibiotics Branded , by Region USD Million (2021-2026)
• Table 324. Oral Antibiotics Generic , by Region USD Million (2021-2026)
• Table 325. Oral Antibiotics: by Application(USD Million)
• Table 326. Oral Antibiotics Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)) , by Region USD Million (2021-2026)
• Table 327. Oral Antibiotics Urinary Acquired Tract Infections (UTIS) , by Region USD Million (2021-2026)
• Table 328. Oral Antibiotics Dental (Combination, and Monotherapies) , by Region USD Million (2021-2026)
• Table 329. Oral Antibiotics Others , by Region USD Million (2021-2026)
• Table 330. Oral Antibiotics: by Spectrum of Activity(USD Million)
• Table 331. Oral Antibiotics Broad-Spectrum Antibiotic , by Region USD Million (2021-2026)
• Table 332. Oral Antibiotics Narrow-Spectrum Antibiotic , by Region USD Million (2021-2026)
• Table 333. Oral Antibiotics: by Drug Origin(USD Million)
• Table 334. Oral Antibiotics Natural , by Region USD Million (2021-2026)
• Table 335. Oral Antibiotics Semisynthetic , by Region USD Million (2021-2026)
• Table 336. Oral Antibiotics Synthetic , by Region USD Million (2021-2026)
• Table 337. Oral Antibiotics: by Class(USD Million)
• Table 338. Oral Antibiotics Beta-Lactam and Beta-Lactamase Inhibitors , by Region USD Million (2021-2026)
• Table 339. Oral Antibiotics Quinolone , by Region USD Million (2021-2026)
• Table 340. Oral Antibiotics Macrolide , by Region USD Million (2021-2026)
• Table 341. Oral Antibiotics Others , by Region USD Million (2021-2026)
• Table 342. South America Oral Antibiotics, by Country USD Million (2021-2026)
• Table 343. South America Oral Antibiotics, by Type USD Million (2021-2026)
• Table 344. South America Oral Antibiotics, by Application USD Million (2021-2026)
• Table 345. South America Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 346. South America Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 347. South America Oral Antibiotics, by Class USD Million (2021-2026)
• Table 348. Brazil Oral Antibiotics, by Type USD Million (2021-2026)
• Table 349. Brazil Oral Antibiotics, by Application USD Million (2021-2026)
• Table 350. Brazil Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 351. Brazil Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 352. Brazil Oral Antibiotics, by Class USD Million (2021-2026)
• Table 353. Argentina Oral Antibiotics, by Type USD Million (2021-2026)
• Table 354. Argentina Oral Antibiotics, by Application USD Million (2021-2026)
• Table 355. Argentina Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 356. Argentina Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 357. Argentina Oral Antibiotics, by Class USD Million (2021-2026)
• Table 358. Rest of South America Oral Antibiotics, by Type USD Million (2021-2026)
• Table 359. Rest of South America Oral Antibiotics, by Application USD Million (2021-2026)
• Table 360. Rest of South America Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 361. Rest of South America Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 362. Rest of South America Oral Antibiotics, by Class USD Million (2021-2026)
• Table 363. Asia Pacific Oral Antibiotics, by Country USD Million (2021-2026)
• Table 364. Asia Pacific Oral Antibiotics, by Type USD Million (2021-2026)
• Table 365. Asia Pacific Oral Antibiotics, by Application USD Million (2021-2026)
• Table 366. Asia Pacific Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 367. Asia Pacific Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 368. Asia Pacific Oral Antibiotics, by Class USD Million (2021-2026)
• Table 369. China Oral Antibiotics, by Type USD Million (2021-2026)
• Table 370. China Oral Antibiotics, by Application USD Million (2021-2026)
• Table 371. China Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 372. China Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 373. China Oral Antibiotics, by Class USD Million (2021-2026)
• Table 374. Japan Oral Antibiotics, by Type USD Million (2021-2026)
• Table 375. Japan Oral Antibiotics, by Application USD Million (2021-2026)
• Table 376. Japan Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 377. Japan Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 378. Japan Oral Antibiotics, by Class USD Million (2021-2026)
• Table 379. India Oral Antibiotics, by Type USD Million (2021-2026)
• Table 380. India Oral Antibiotics, by Application USD Million (2021-2026)
• Table 381. India Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 382. India Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 383. India Oral Antibiotics, by Class USD Million (2021-2026)
• Table 384. South Korea Oral Antibiotics, by Type USD Million (2021-2026)
• Table 385. South Korea Oral Antibiotics, by Application USD Million (2021-2026)
• Table 386. South Korea Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 387. South Korea Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 388. South Korea Oral Antibiotics, by Class USD Million (2021-2026)
• Table 389. Taiwan Oral Antibiotics, by Type USD Million (2021-2026)
• Table 390. Taiwan Oral Antibiotics, by Application USD Million (2021-2026)
• Table 391. Taiwan Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 392. Taiwan Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 393. Taiwan Oral Antibiotics, by Class USD Million (2021-2026)
• Table 394. Australia Oral Antibiotics, by Type USD Million (2021-2026)
• Table 395. Australia Oral Antibiotics, by Application USD Million (2021-2026)
• Table 396. Australia Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 397. Australia Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 398. Australia Oral Antibiotics, by Class USD Million (2021-2026)
• Table 399. Rest of Asia-Pacific Oral Antibiotics, by Type USD Million (2021-2026)
• Table 400. Rest of Asia-Pacific Oral Antibiotics, by Application USD Million (2021-2026)
• Table 401. Rest of Asia-Pacific Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 402. Rest of Asia-Pacific Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 403. Rest of Asia-Pacific Oral Antibiotics, by Class USD Million (2021-2026)
• Table 404. Europe Oral Antibiotics, by Country USD Million (2021-2026)
• Table 405. Europe Oral Antibiotics, by Type USD Million (2021-2026)
• Table 406. Europe Oral Antibiotics, by Application USD Million (2021-2026)
• Table 407. Europe Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 408. Europe Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 409. Europe Oral Antibiotics, by Class USD Million (2021-2026)
• Table 410. Germany Oral Antibiotics, by Type USD Million (2021-2026)
• Table 411. Germany Oral Antibiotics, by Application USD Million (2021-2026)
• Table 412. Germany Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 413. Germany Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 414. Germany Oral Antibiotics, by Class USD Million (2021-2026)
• Table 415. France Oral Antibiotics, by Type USD Million (2021-2026)
• Table 416. France Oral Antibiotics, by Application USD Million (2021-2026)
• Table 417. France Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 418. France Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 419. France Oral Antibiotics, by Class USD Million (2021-2026)
• Table 420. Italy Oral Antibiotics, by Type USD Million (2021-2026)
• Table 421. Italy Oral Antibiotics, by Application USD Million (2021-2026)
• Table 422. Italy Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 423. Italy Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 424. Italy Oral Antibiotics, by Class USD Million (2021-2026)
• Table 425. United Kingdom Oral Antibiotics, by Type USD Million (2021-2026)
• Table 426. United Kingdom Oral Antibiotics, by Application USD Million (2021-2026)
• Table 427. United Kingdom Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 428. United Kingdom Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 429. United Kingdom Oral Antibiotics, by Class USD Million (2021-2026)
• Table 430. Netherlands Oral Antibiotics, by Type USD Million (2021-2026)
• Table 431. Netherlands Oral Antibiotics, by Application USD Million (2021-2026)
• Table 432. Netherlands Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 433. Netherlands Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 434. Netherlands Oral Antibiotics, by Class USD Million (2021-2026)
• Table 435. Rest of Europe Oral Antibiotics, by Type USD Million (2021-2026)
• Table 436. Rest of Europe Oral Antibiotics, by Application USD Million (2021-2026)
• Table 437. Rest of Europe Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 438. Rest of Europe Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 439. Rest of Europe Oral Antibiotics, by Class USD Million (2021-2026)
• Table 440. MEA Oral Antibiotics, by Country USD Million (2021-2026)
• Table 441. MEA Oral Antibiotics, by Type USD Million (2021-2026)
• Table 442. MEA Oral Antibiotics, by Application USD Million (2021-2026)
• Table 443. MEA Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 444. MEA Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 445. MEA Oral Antibiotics, by Class USD Million (2021-2026)
• Table 446. Middle East Oral Antibiotics, by Type USD Million (2021-2026)
• Table 447. Middle East Oral Antibiotics, by Application USD Million (2021-2026)
• Table 448. Middle East Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 449. Middle East Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 450. Middle East Oral Antibiotics, by Class USD Million (2021-2026)
• Table 451. Africa Oral Antibiotics, by Type USD Million (2021-2026)
• Table 452. Africa Oral Antibiotics, by Application USD Million (2021-2026)
• Table 453. Africa Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 454. Africa Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 455. Africa Oral Antibiotics, by Class USD Million (2021-2026)
• Table 456. North America Oral Antibiotics, by Country USD Million (2021-2026)
• Table 457. North America Oral Antibiotics, by Type USD Million (2021-2026)
• Table 458. North America Oral Antibiotics, by Application USD Million (2021-2026)
• Table 459. North America Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 460. North America Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 461. North America Oral Antibiotics, by Class USD Million (2021-2026)
• Table 462. United States Oral Antibiotics, by Type USD Million (2021-2026)
• Table 463. United States Oral Antibiotics, by Application USD Million (2021-2026)
• Table 464. United States Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 465. United States Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 466. United States Oral Antibiotics, by Class USD Million (2021-2026)
• Table 467. Canada Oral Antibiotics, by Type USD Million (2021-2026)
• Table 468. Canada Oral Antibiotics, by Application USD Million (2021-2026)
• Table 469. Canada Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 470. Canada Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 471. Canada Oral Antibiotics, by Class USD Million (2021-2026)
• Table 472. Mexico Oral Antibiotics, by Type USD Million (2021-2026)
• Table 473. Mexico Oral Antibiotics, by Application USD Million (2021-2026)
• Table 474. Mexico Oral Antibiotics, by Spectrum of Activity USD Million (2021-2026)
• Table 475. Mexico Oral Antibiotics, by Drug Origin USD Million (2021-2026)
• Table 476. Mexico Oral Antibiotics, by Class USD Million (2021-2026)
• Table 477. Oral Antibiotics Sales: by Type(KG)
• Table 478. Oral Antibiotics Sales Branded , by Region KG (2021-2026)
• Table 479. Oral Antibiotics Sales Generic , by Region KG (2021-2026)
• Table 480. Oral Antibiotics Sales: by Application(KG)
• Table 481. Oral Antibiotics Sales Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)) , by Region KG (2021-2026)
• Table 482. Oral Antibiotics Sales Urinary Acquired Tract Infections (UTIS) , by Region KG (2021-2026)
• Table 483. Oral Antibiotics Sales Dental (Combination, and Monotherapies) , by Region KG (2021-2026)
• Table 484. Oral Antibiotics Sales Others , by Region KG (2021-2026)
• Table 485. Oral Antibiotics Sales: by Spectrum of Activity(KG)
• Table 486. Oral Antibiotics Sales Broad-Spectrum Antibiotic , by Region KG (2021-2026)
• Table 487. Oral Antibiotics Sales Narrow-Spectrum Antibiotic , by Region KG (2021-2026)
• Table 488. Oral Antibiotics Sales: by Drug Origin(KG)
• Table 489. Oral Antibiotics Sales Natural , by Region KG (2021-2026)
• Table 490. Oral Antibiotics Sales Semisynthetic , by Region KG (2021-2026)
• Table 491. Oral Antibiotics Sales Synthetic , by Region KG (2021-2026)
• Table 492. Oral Antibiotics Sales: by Class(KG)
• Table 493. Oral Antibiotics Sales Beta-Lactam and Beta-Lactamase Inhibitors , by Region KG (2021-2026)
• Table 494. Oral Antibiotics Sales Quinolone , by Region KG (2021-2026)
• Table 495. Oral Antibiotics Sales Macrolide , by Region KG (2021-2026)
• Table 496. Oral Antibiotics Sales Others , by Region KG (2021-2026)
• Table 497. South America Oral Antibiotics Sales, by Country KG (2021-2026)
• Table 498. South America Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 499. South America Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 500. South America Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 501. South America Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 502. South America Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 503. Brazil Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 504. Brazil Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 505. Brazil Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 506. Brazil Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 507. Brazil Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 508. Argentina Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 509. Argentina Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 510. Argentina Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 511. Argentina Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 512. Argentina Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 513. Rest of South America Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 514. Rest of South America Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 515. Rest of South America Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 516. Rest of South America Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 517. Rest of South America Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 518. Asia Pacific Oral Antibiotics Sales, by Country KG (2021-2026)
• Table 519. Asia Pacific Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 520. Asia Pacific Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 521. Asia Pacific Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 522. Asia Pacific Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 523. Asia Pacific Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 524. China Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 525. China Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 526. China Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 527. China Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 528. China Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 529. Japan Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 530. Japan Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 531. Japan Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 532. Japan Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 533. Japan Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 534. India Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 535. India Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 536. India Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 537. India Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 538. India Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 539. South Korea Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 540. South Korea Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 541. South Korea Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 542. South Korea Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 543. South Korea Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 544. Taiwan Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 545. Taiwan Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 546. Taiwan Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 547. Taiwan Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 548. Taiwan Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 549. Australia Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 550. Australia Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 551. Australia Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 552. Australia Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 553. Australia Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 554. Rest of Asia-Pacific Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 555. Rest of Asia-Pacific Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 556. Rest of Asia-Pacific Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 557. Rest of Asia-Pacific Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 558. Rest of Asia-Pacific Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 559. Europe Oral Antibiotics Sales, by Country KG (2021-2026)
• Table 560. Europe Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 561. Europe Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 562. Europe Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 563. Europe Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 564. Europe Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 565. Germany Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 566. Germany Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 567. Germany Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 568. Germany Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 569. Germany Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 570. France Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 571. France Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 572. France Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 573. France Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 574. France Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 575. Italy Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 576. Italy Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 577. Italy Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 578. Italy Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 579. Italy Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 580. United Kingdom Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 581. United Kingdom Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 582. United Kingdom Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 583. United Kingdom Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 584. United Kingdom Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 585. Netherlands Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 586. Netherlands Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 587. Netherlands Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 588. Netherlands Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 589. Netherlands Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 590. Rest of Europe Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 591. Rest of Europe Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 592. Rest of Europe Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 593. Rest of Europe Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 594. Rest of Europe Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 595. MEA Oral Antibiotics Sales, by Country KG (2021-2026)
• Table 596. MEA Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 597. MEA Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 598. MEA Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 599. MEA Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 600. MEA Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 601. Middle East Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 602. Middle East Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 603. Middle East Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 604. Middle East Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 605. Middle East Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 606. Africa Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 607. Africa Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 608. Africa Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 609. Africa Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 610. Africa Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 611. North America Oral Antibiotics Sales, by Country KG (2021-2026)
• Table 612. North America Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 613. North America Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 614. North America Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 615. North America Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 616. North America Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 617. United States Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 618. United States Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 619. United States Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 620. United States Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 621. United States Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 622. Canada Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 623. Canada Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 624. Canada Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 625. Canada Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 626. Canada Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 627. Mexico Oral Antibiotics Sales, by Type KG (2021-2026)
• Table 628. Mexico Oral Antibiotics Sales, by Application KG (2021-2026)
• Table 629. Mexico Oral Antibiotics Sales, by Spectrum of Activity KG (2021-2026)
• Table 630. Mexico Oral Antibiotics Sales, by Drug Origin KG (2021-2026)
• Table 631. Mexico Oral Antibiotics Sales, by Class KG (2021-2026)
• Table 632. Oral Antibiotics: by Type(USD/Units)
• Table 633. Research Programs/Design for This Report
• Table 634. Key Data Information from Secondary Sources
• Table 635. Key Data Information from Primary Sources

• Figure 1. Porters Five Forces
• Figure 2. Supply/Value Chain
• Figure 3. PESTEL analysis
• Figure 4. Global Oral Antibiotics: by Type USD Million (2015-2020)
• Figure 5. Global Oral Antibiotics: by Application USD Million (2015-2020)
• Figure 6. Global Oral Antibiotics: by Spectrum of Activity USD Million (2015-2020)
• Figure 7. Global Oral Antibiotics: by Drug Origin USD Million (2015-2020)
• Figure 8. Global Oral Antibiotics: by Class USD Million (2015-2020)
• Figure 9. South America Oral Antibiotics Share (%), by Country
• Figure 10. Asia Pacific Oral Antibiotics Share (%), by Country
• Figure 11. Europe Oral Antibiotics Share (%), by Country
• Figure 12. MEA Oral Antibiotics Share (%), by Country
• Figure 13. North America Oral Antibiotics Share (%), by Country
• Figure 14. Global Oral Antibiotics: by Type KG (2015-2020)
• Figure 15. Global Oral Antibiotics: by Application KG (2015-2020)
• Figure 16. Global Oral Antibiotics: by Spectrum of Activity KG (2015-2020)
• Figure 17. Global Oral Antibiotics: by Drug Origin KG (2015-2020)
• Figure 18. Global Oral Antibiotics: by Class KG (2015-2020)
• Figure 19. South America Oral Antibiotics Share (%), by Country
• Figure 20. Asia Pacific Oral Antibiotics Share (%), by Country
• Figure 21. Europe Oral Antibiotics Share (%), by Country
• Figure 22. MEA Oral Antibiotics Share (%), by Country
• Figure 23. North America Oral Antibiotics Share (%), by Country
• Figure 24. Global Oral Antibiotics: by Type USD/Units (2015-2020)
• Figure 25. Global Oral Antibiotics share by Players 2020 (%)
• Figure 26. Global Oral Antibiotics share by Players (Top 3) 2020(%)
• Figure 27. Global Oral Antibiotics share by Players (Top 5) 2020(%)
• Figure 28. BCG Matrix for key Companies
• Figure 29. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
• Figure 30. Abbott Laboratories (United States) Revenue: by Geography 2020
• Figure 31. Allergan Plc. (Ireland) Revenue, Net Income and Gross profit
• Figure 32. Allergan Plc. (Ireland) Revenue: by Geography 2020
• Figure 33. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
• Figure 34. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
• Figure 35. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
• Figure 36. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
• Figure 37. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
• Figure 38. Merck & Co. Inc. (United States) Revenue: by Geography 2020
• Figure 39. Mylan N.V. (United States) Revenue, Net Income and Gross profit
• Figure 40. Mylan N.V. (United States) Revenue: by Geography 2020
• Figure 41. Novartis International AG (Sandoz) Revenue, Net Income and Gross profit
• Figure 42. Novartis International AG (Sandoz) Revenue: by Geography 2020
• Figure 43. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
• Figure 44. Pfizer Inc. (United States) Revenue: by Geography 2020
• Figure 45. Sanofi (France) Revenue, Net Income and Gross profit
• Figure 46. Sanofi (France) Revenue: by Geography 2020
• Figure 47. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
• Figure 48. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
• Figure 49. Global Oral Antibiotics: by Type USD Million (2021-2026)
• Figure 50. Global Oral Antibiotics: by Application USD Million (2021-2026)
• Figure 51. Global Oral Antibiotics: by Spectrum of Activity USD Million (2021-2026)
• Figure 52. Global Oral Antibiotics: by Drug Origin USD Million (2021-2026)
• Figure 53. Global Oral Antibiotics: by Class USD Million (2021-2026)
• Figure 54. South America Oral Antibiotics Share (%), by Country
• Figure 55. Asia Pacific Oral Antibiotics Share (%), by Country
• Figure 56. Europe Oral Antibiotics Share (%), by Country
• Figure 57. MEA Oral Antibiotics Share (%), by Country
• Figure 58. North America Oral Antibiotics Share (%), by Country
• Figure 59. Global Oral Antibiotics: by Type KG (2021-2026)
• Figure 60. Global Oral Antibiotics: by Application KG (2021-2026)
• Figure 61. Global Oral Antibiotics: by Spectrum of Activity KG (2021-2026)
• Figure 62. Global Oral Antibiotics: by Drug Origin KG (2021-2026)
• Figure 63. Global Oral Antibiotics: by Class KG (2021-2026)
• Figure 64. South America Oral Antibiotics Share (%), by Country
• Figure 65. Asia Pacific Oral Antibiotics Share (%), by Country
• Figure 66. Europe Oral Antibiotics Share (%), by Country
• Figure 67. MEA Oral Antibiotics Share (%), by Country
• Figure 68. North America Oral Antibiotics Share (%), by Country
• Figure 69. Global Oral Antibiotics: by Type USD/Units (2021-2026)

• Abbott Laboratories (United States)
• Allergan Plc. (Ireland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline plc (United Kingdom)
• Merck & Co. Inc. (United States)
• Mylan N.V. (United States)
• Novartis International AG (Sandoz)
• Pfizer Inc. (United States)
• Sanofi (France)
• Teva Pharmaceutical Industries Ltd. (Israel)